BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29100275)

  • 1. A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.
    Li Q; Yang Z; Fan J; He J; Zhang B; Yang H; Xie X; Tang Z; Li H; Qiao Y; Zhang P
    Oncotarget; 2017 Sep; 8(44):75864-75873. PubMed ID: 29100275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.
    van Herk-Sukel MP; van de Poll-Franse LV; Creemers GJ; Lemmens VE; van der Linden PD; Herings RM; Coebergh JW; Voogd AC
    Breast J; 2013; 19(4):394-401. PubMed ID: 23663128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.
    Jung L; Miske A; Indorf A; Nelson K; Gadi VK; Banda K
    Clin Breast Cancer; 2022 Apr; 22(3):e310-e318. PubMed ID: 34753632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
    Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
    J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
    ; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
    Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
    Lopez M; Di Lauro L; Viola G; Conti F; Foggi P; Vici P
    Clin Ter; 2009; 160(6):489-97. PubMed ID: 20198293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
    Hilaj E; Ymeri A; Shpati KP
    Cureus; 2020 Feb; 12(2):e7117. PubMed ID: 32257663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study].
    Xiu M; Lu Y; Wang X; Fan Y; Li Q; Li Q; Wang JY; Luo Y; Cai RG; Chen SS; Yuan P; Ma F; Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):709-716. PubMed ID: 37580278
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    ;
    Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study.
    Guo F; Yi Z; Wang W; Han Y; Yu P; Zhang S; Ouyang Q; Yan M; Wang X; Hu X; Jiang Z; Huang T; Tong Z; Wang S; Yin Y; Li H; Yang R; Yang H; Teng Y; Sun T; Cai L; Li H; Chen X; He J; Liu X; Yang S; Fan J; Qiao Y; Wang J; Xu B
    Cancer Med; 2021 Oct; 10(19):6744-6761. PubMed ID: 34472719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.